Santos Alexandre, Penfold Scott, Gorayski Peter, Le Hien
Australian Bragg Centre for Proton Therapy and Research, North Terrace, Adelaide, SA 5000, Australia.
Department of Radiation Oncology, Royal Adelaide Hospital, Port Road, Adelaide, SA 5000, Australia.
Cancers (Basel). 2022 May 2;14(9):2271. doi: 10.3390/cancers14092271.
Hypofractionated radiotherapy is an attractive approach for minimizing patient burden and treatment cost. Technological advancements in external beam radiotherapy (EBRT) delivery and image guidance have resulted in improved targeting and conformality of the absorbed dose to the disease and a reduction in dose to healthy tissue. These advances in EBRT have led to an increasing adoption and interest in hypofractionation. Furthermore, for many treatment sites, proton beam therapy (PBT) provides an improved absorbed dose distribution compared to X-ray (photon) EBRT. In the past 10 years there has been a notable increase in reported clinical data involving hypofractionation with PBT, reflecting the interest in this treatment approach. This review will discuss the reported clinical data and radiobiology of hypofractionated PBT. Over 50 published manuscripts reporting clinical results involving hypofractionation and PBT were included in this review, ~90% of which were published since 2010. The most common treatment regions reported were prostate, lung and liver, making over 70% of the reported results. Many of the reported clinical data indicate that hypofractionated PBT can be well tolerated, however future clinical trials are still needed to determine the optimal fractionation regime.
大分割放疗是一种减轻患者负担和降低治疗成本的有吸引力的方法。外照射放疗（EBRT）技术的进步以及图像引导技术，使得对疾病的吸收剂量的靶向性和适形性得到改善，同时减少了对健康组织的剂量。EBRT的这些进展导致大分割放疗的应用和关注度不断增加。此外，对于许多治疗部位，质子束治疗（PBT）与X射线（光子）EBRT相比，提供了更好的吸收剂量分布。在过去10年中，报道的涉及PBT大分割放疗的临床数据显著增加，这反映了对这种治疗方法的兴趣。本综述将讨论报道的PBT大分割放疗的临床数据和放射生物学。本综述纳入了50多篇报道涉及大分割放疗和PBT临床结果的已发表手稿，其中约90%是2010年以后发表的。报道最多的治疗区域是前列腺、肺和肝脏，占报道结果的70%以上。许多报道的临床数据表明，PBT大分割放疗耐受性良好，但仍需要未来的临床试验来确定最佳分割方案。
